May 10, 2022
Medical Funding Professionals (MFP) is pleased to announce that Kurve Therapeutics has engaged MFP to implement the Capital Planning Valuation Strategy™ Co-Chaired by Scott Pantel of LSI and Stephen Brock of MFP in preparation of the company’s Regulation A+ offering.
Kurve Therapeutics is a specialty-drug company focused on next-generation treatments for neurodegenerative diseases. Current therapies for these disorders, especially complex molecules such as monoclonal antibodies, stem cells and larger peptides, have trouble crossing the blood brain barrier (BBB). Kurve’s patented Controlled Particle Dispersion® intranasal drug delivery technology creates a precisely-controlled turbulent flow that navigates the curved, complex geometry of the nasal cavity and accesses the olfactory region, bypassing the BBB, resulting in a delivery of up to 30 times more medicine to the brain than oral or intravenous delivery.
“This is the future of how central nervous system disorders are treated,” says Kurve founder Marc Giroux. “Delivering the drug as directly as possible to the point of action is a significant breakthrough. We’ve been successfully hitting our milestones and are eager to get this technology out to the world.”
Kurve has completed phase II and phase IIb clinical trials and have has 17 successful studies published in peer-reviewed journals. Following their most recent phase IIb trial, Laurie Ryan, PhD, Chief of the Dementias of Aging Branch of the National Institute on Aging, which funded the study, had this to say: "It's encouraging to see that if you do get insulin to the brain, you see changes in biomarkers. That's important, but it needs to be tested. It's got to go to a larger phase III study."
And that’s what Kurve now plans to do: a larger phase III study, the final step needed for FDA approval before going to market.
Watch Kurve Therapeutics', CEO, Marc Giroux Investor Presentation at LSI USA '22
Phase III trials are expensive, though—the median expense for a single phase III trial is $19 million. “We knew we needed more than just money—we needed a strategic plan for capital to see us through the phase III trials and on to execute our go-to-market strategy,” says Giroux. “That’s what Medical Funding Professionals has outlined for us, and we look forward to working with them to help us reach those next milestones.”
“We’re thrilled to be working with Kurve,” says Medical Funding Professionals CEO Stephen Brock. “We have all been touched, directly or indirectly, by the devastating effects of memory loss and dementia in our loved ones. We’re committed to doing everything we can to see Kurve’s breakthrough technology get out to patients, and helping the founders stay in both financial and governance control of the company as they grow.”
“This is why I’m so committed to the medtech industry,” says Scott Pantel, CEO of medtech market research firm Life Science Intelligence, an MFP strategic partner. “These are potentially life-changing technologies and all too often they never make it to the market because of a lack of access to capital. Stephen Brock is deeply committed to making sure they do, and I look forward to bringing that commitment to our network.”
“Kurve’s technology is a potential game-changer,” continues Pantel. “I look forward to following their growth.”
Kurve Therapeutics will be among 100 vetted presenting companies attending the LSI Europe ’22 Emerging Medtech Summit in London taking place on September 21-24, 2022. In addition to company presentations, the event will feature panel sessions with investors, one-on-one meetings, and vast networking opportunities with leading medtech investors, strategics, and industry insiders.
About Kurve Therapeutics
Kurve Therapeutics is developing disease-modifying drug/device combination therapies with demonstrated clinical efficacy in cognitive aging, neurodegenerative diseases and related disorders, including Alzheimer’s disease, Parkinson’s, ALS, Multiple Sclerosis, diabetes-related neurodegenerative disorders, and general age-related memory loss. The company’s patented Controlled Particle Dispersion® intranasal drug delivery technology offers faster, more effective drug delivery to the central nervous system, allowing for significantly lower dosages, reducing drug side effects and costs.
Kurve Therapeutics is considering an offering of securities exempt from registration under the Securities Act of 1933, but has not determined a specific exemption from registration it intends to rely on for the subsequent offer and sale of the securities. No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until Kurve determines the exemption under which the offering is intended to be conducted and, where applicable, the filing, disclosure, or qualification requirements of such exemption are met. A person's indication of interest involves no obligation or commitment of any kind.
About Medical Funding Professionals
Medical Funding Professionals is a registered investment advisor firm providing capital and cash flow planning solutions to the medical industry, including life sciences, biotech, medtech, and pharmaceutical sectors. Their Capital Planning Valuation Strategy™ (CPVS) ensures founders and key executives maintain control of their companies as they raise capital and grow. Medical Funding Professionals compliments its advisory services by providing further guidance on how to utilize the updated private company exemptions such as 506c for accredited investors and Reg A+ which allows a company to raise up to $75M from both accredited and non-accredited every 12 months.
About Life Science Intelligence
LSI is a medical technology-focused market intelligence & consulting company that helps medtech executives make informed strategic decisions by better understanding market dynamics, trends, opportunities and the competitive landscape.
Regulation A+ Disclaimer
This communication may be deemed to be a solicitation of interest under Regulation A under the Securities Act of 1933, in which case the following apply: